



REFERENCES

## REFERENCES

- [1] Galia E., Horton J., & Dressman J. B. (1999). Albendazole Generics – A Comparative in vitro study. Pharmaceutical research, 16 (12), 1871-1875.
- [2] Hennekens CH., Dyken ML., & Fuster V. (1997). Aspirin as a therapeutic agent in cardiovascular disease; a statement for healthcare professionals from the American Heart Association, Circulation, 96(8), 2751-2753.
- [3] World Health Organization. (1999). Essential Drugs and Medicines Policy in WHO Model List of Essential Drugs, (11<sup>th</sup> ed.).
- [4] Yoshioka, Sumie & Stella, Valentino J. (2000). Stability of drugs and dosage forms. New York: Kluwer Academic/Plenum.
- [5] Sokhan Chroeng & Phirun Ung. (2001). Cambodia Assessment: Targeting improved access, quality of products and services in Management sciences for health. Phnom Penh: SEAM Conference 2001.
- [6] Veronica Waiford. (2000). Cambodia Country Health Briefing Paper. London: Department for International Development Resource Center for Health Sector Reform.
- [7] Committee for Research and Study on Counterfeit Drug. (2001). Study report on counterfeit and substandard drugs in Cambodia. Phnom Penh: Cambodian Ministry of Health with WHO.
- [8] Economic, Social and Cultural Rights. (January 30, 2001). Health Care in Cambodia (E/CN.4/2001/NGO/63). Asean Legal Resource Center. Internet Site 2001. Retrieved on April 8, 2003 from <http://www.alrc.net/mainfile.php/57written/29/>
- [9] Yan Y. et al. (2000). Counterfeit Drugs: Ministry of Health and Illegal Drugstores and Counterfeit Drugs. Journal of Pharmacist Association of Cambodia / PAC, 4, 20- 21.
- [10] Fake and Poor-Quality Drugs Common in Less-Developed Countries Hospital Management Net. (June 16, 2001). The Lancet (pp. 1-2). Retrieved on May 13, 2002 from: <http://www.hospitalmanagement.net/informer/library/library11/>.

- [11] Chanin C., Loung Khun V., & Chaweewon B. (2002). Rational drug use in Cambodia: Study of three pilot health centers in Kampong Thom province. Southeast Asian Journal of Tropical Medicine and Public Health, 33(2), 418-424.
- [12] Klaus F. (1979). Aspirin. Analytical Profiles of Drug Substances. New York: Academic Press.
- [13] Tamar N. (1999). An Aspirin a Day. U.S. Food and Drug Administration. FDA Consumer magazine, 1-5.
- [14] Margaret D. & Fred W. (1994). An Ancient Herbal Remedy Today: Aspirin. Medicines the Inside Story. ChemSource. Chemistry in Medicine (MEDI). Washington-Lee High School (Vol. 2, pp. 1-4). Retrieved on May 10, 2003 from: [http://www.medicines-inside.com/ep\\_lesnt.html](http://www.medicines-inside.com/ep_lesnt.html).
- [15] Lund W. (1994). The Pharmaceutical Codex: Principle and Practice of Pharmaceutics (12<sup>th</sup> ed.). London: The Pharmaceutical Press.
- [16] Alfonso R. G. (1995). Remington: The Science and Practice of Pharmacy. (19<sup>th</sup> ed.). Easton: Mack.
- [17] Sasan B. (1989). The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals (11<sup>th</sup> ed.). Rahway: Merck & Co.
- [18] Singh S. (1999). Drug stability testing and shelf-life determination according to international guidelines. Pharmaceutical Technology Asia, 11(11), 14-26.
- [19] Kenneth A.C., Gordon L. A., & Valentino J. S. (1979). A Handbook for Pharmacists: Chemical Stability of Pharmaceuticals (2<sup>nd</sup> ed.). New York: John & Sons.
- [20] The British Pharmacopoeia Commission. (1993). British Pharmacopoeia. London: Her Majesty's Stationery.
- [21] Alfonso R. G. (1995). Remington: Reaction Kinetics. (19<sup>th</sup> ed.). Easton: Mack.
- [22] Michael J. S., James C. P., & Won J. H. (1993). The stability of aspirin in moisture containing direct compression tablet formulation. Drug Development and Industrial Pharmacy, 19(6), 729-738.
- [23] Kelly C.A. (1970). Determination of the Decomposition of Aspirin. Journal of Pharmaceutical Sciences, 59 (8), 1053-1079.

- [24] Pilatluck S., Achara Y., & Chaipat T. (1995). Free Salicylic Acid in Analgesic-Antipyretic Sachets. Bulletin of Department of Medical Sciences, 37 (4), 353-356.
- [25] Ulla R. (1993). Determination of Acetylsalicylic Acid and Metabolites in Biological Fluids by High-Performance Liquid Chromatography. Journal of Chromatography, ( 272), 325-331.
- [26] Gamal A. E.G, et al. (1986). Molecular behavior, dissolution characteristics and chemical stability of aspirin in the ground mixture and in the inclusion complex with di-O-methyl- $\beta$ -cyclodextrin. International Journal of Pharmaceutics, (31), 25-31.
- [27] Albert KS. et al. (1978). Influence of Kaolin-pectin suspension on digoxin bioavailability. Journal of Pharmaceutical Sciences, 67(11), 1582-1586.
- [28] Franz M, & Peek GE. (1982). In vitro adsorption-desorption of fluphenazine dihydrochloride and promazine hydrochloride by microcrystalline cellulose. Journal of Pharmaceutical Sciences, 71(11), 1193-1199.
- [29] Sylvia W. et al. (2000). An investigation into the use of stepwise isothermal high sensitivity DSC as a means of detecting drug-excipient incompatibility. International Journal of Pharmaceutics, (199) 141-150.
- [30] Stephen R.B., Wei X., & Ann W.N. (2001). Chemical reactivity in solid-state pharmaceuticals: formulation implications. Advanced Drug Delivery Reviews, (48) 115-136.
- [31] Mitrevej A. & Gary H.R. (1983). Influence of hydrophilic excipients on the interaction of aspirin and water. International Journal of Pharmaceutics, (14) 243-250.
- [32] Gireesh G., Kenneth A., & David D. (1992). The use of thermal analysis and mass spectrometry to study the solid state behavior in pharmaceutical tablet mixtures. Thermochimica Acta, (196), 267-278.
- [33] Puttiparkhachorn S., Mitrevej A. & Papangkornkij V. (1993). Variation in powder characteristics of indomethacin from various sources. Thai Journal of Pharmaceutical Sciences, 17(1), 5-11.

- [34] Chiou W.L., & Kyle L.E. (1979). Differential thermal, solubility, and aging studies on various sources of digoxin and digitoxin powder: biopharmaceutical implications. Journal of Pharmaceutical Sciences, 68(10), 1224-1229.
- [35] Tromelin A. et al. (1996). Relationship between particle size and dissolution rate of bulk powders and sieving characterized fractions of two qualities of orthoboric acid. Drug Development and Industrial Pharmacy, 22(9&10), 977-986.
- [36] Farin D. & Avnir D. (1992). Use of fractal geometry to determine effects of surface morphology on drug dissolution. Journal of Pharmaceutical Sciences, 81(1), 54-57.
- [37] Simões S., Sousa A., & Figueiredo M. (1996). Dissolution rate studies of pharmaceutical multisized powders – a practical approach using the Coulter method. International Journal of Pharmaceutics, (127), 283-291.
- [38] Simões S., Almeida L.P., & Figueiredo M. (1996). Testing the applicability of classical diffusional models to polydisperse systems. International Journal of Pharmaceutics, (139), 169-176.
- [39] York P. (1983). Solid-state properties of powders in the formulation and processing of solid dosage forms. International Journal of Pharmaceutics, (14), 1-28.
- [40] Katdare A.V., Oddoye D.D., & Bavitz J.F. (1987). Effect of micronization of norfloxacin on tablet properties. Drug Development and Industrial Pharmacy, 13(2), 281-288.
- [41] Narurkar A. et al. (1987). Effect of particle size on the dissolution characteristics of chlorthalidone. Drug Development and Industrial Pharmacy, 13(2), 319-328.
- [42] Bates T.R., & Sequeira J.A. (1975). Bioavailability of micronized greseofulvin from corn oil-in-water emulsion, aqueous suspension, and commercial tablet dosage forms in humans. Journal of Pharmaceutical Sciences, 64(5), 793-797.
- [43] Carstensen J.T., & Musa M.N. (1972). Dissolution rate patterns of log-normally distributed powder. Journal of Pharmaceutical Sciences, 61(2), 223-227.

- [44] Hintz R.J., & Johnson K.C. (1989). The effect of particle size distribution on dissolution rate and oral absorption. International Journal of Pharmaceutics, (51), 9-17.
- [45] Stout P.J.M. et al. (1992). Mauger J.W., Dissolution performance related to particle size distribution for commercially available prednisolone acetate suspensions. Drug Development and Industrial Pharmacy, 18(4), 395-408.
- [46] Lindberg N.O., & Lundstedt T. (1994). The relationship between the dissolution rate and the particle size of prednimustine: a disagreement with the Noyes-Whitney equation. Drug Development and Industrial Pharmacy, 20(16), 2547-2550.
- [47] Kitamori N. & Iga K. (1978). Dissolution of nonspherical powders. Journal of Pharmaceutical Sciences, 67(12), 1674-1981.
- [48] Fernández-Hervás M.J. et al. (1994). Use of fractal on the characterization of particles morphology: application to the diclofenac hydroxyethylpyrrolidine salt. International Journal of Pharmaceutics, (108), 187-194.
- [49] Haleblan J., & McCrone W. (1969). Pharmaceutical applications of polymorphism. Journal of Pharmaceutical Sciences, 58(8), 911-929.
- [50] Haleblan J.K. (1975). Characterization of habits and crystalline modification of solids and their pharmaceutical applications. Journal of Pharmaceutical Sciences, 64(8), 1269-1288.
- [51] Brittain H.G. (1994). Perspective on polymorphism. Pharmaceutical Technology, 18 (8), 50-52.
- [52] De Villiers M.M. et al. (1995). Correlation between physico-chemical properties and cohesive behavior of furosemide crystal modifications. Drug Development and Industrial Pharmacy, 21(17), 1975-1988.
- [53] Borka L. (1991). Review on crystal polymorphism of substances in the European Pharmacopoeia. Pharm Acta Helv, 66(1), 16-22.
- [54] Wall G.M. (1986). Pharmaceutical applications of drug crystal studies. Pharm Manufac, 3(2), 33-42.

- [55] Gecse A. et al. (1969). Gastrointestinal absorption of two polymorphic forms of aspirin. Journal of Pharmaceutical Pharmacology, (21), 701-702.
- [56] Stagner W.C., & Keith Guillory J. (1979). Physical characterization of solid iopanoic acid forms. Journal of Pharmaceutical Sciences, 68(8), 1005-1009.
- [57] Aguiar A.J., & Zelmer J.E. (1969). Dissolution behavior of polymorphs of chloramphenicol palmitate and mefenamic acid. Journal of Pharmaceutical Sciences, 58(8), 983-987.
- [58] Shibata M. et al. (1983). X-ray Structural Studies and Physicochemical Properties of Cimetidine Polymorphism. Journal of Pharmaceutical Sciences, 72(12), 1436-1441.
- [59] Kokubo H. et al. (1987). Bioavailability and inhibitory effect for stress ulcer of cimetidine polymorphs in rats. International Journal of Pharmaceutics, (35), 181-183.
- [60] Ibrahim H.G., Pisano F., & Bruno A. (1977). Polymorphism of Phenylbutazone: Properties and Compressional Behavior of Crystals. Journal of Pharmaceutical Sciences, 66(5), 669-673.
- [61] Tuladhar M.D., Carless J.E., & Summers M.P. (1983). Thermal behaviour and dissolution properties of phenylbutazone polymorphs. Journal of Pharmaceutical Pharmacology, (35), 208-214.
- [62] Tuladhar M.D., Carless J.E., & Summers M.P. (1983). The effect of polymorphism, particle size compression pressure on the dissolution rate of phenylbutazone tablets. Journal of Pharmaceuticla Pharmacology, (35), 269-274.
- [63] Allen P.V. et al. (1978). Physical characterization of erythromycin: anhydrate, monohydrate, and dihydrate crystalline solids. Journal of Pharmaceutical Sciences, 67(8), 1087-1092.
- [64] Fiese E.F., & Hagen T.A. (1986). Preformulation. In: Lachman L., Lieberman H.A., and Kanig J.L., editors. The Theory and Practice of Industrial Pharmacy. (3<sup>rd</sup> ed.). Philadelphia: Lea & Febiger.

- [65] Andrès C. et al. (1995). Influence of the parameters molecular structure and granularity on the compactibility of a powder. Drug Development and Industrial Pharmacy, 21(16), 1875-1885.
- [66] Desai D.S. et al. (1993). Physical interactions of magnesium stearate with starch-derived disintegrants and their effects on capsule and tablet dissolution. International Journal of Pharmaceutical Sciences, (91), 217-226.
- [67] Chowhan Z.T., & Chi L.H. (1986). Drug-Excipient Interactions resulting from powder mixing IV: role of lubricants and their effect on in vitro dissolution. Journal of Pharmaceutical Sciences, 75(6), 542-545.
- [68] Frattini C., & Simioni L. (1984). Should magnesium stearate be assessed in the formulation of solid dosage forms by weight or surface area? Drug Development and Industrial Pharmacy, 10(7), 1117-1130.
- [69] McCarty J.A. (2003). Direct powder blends for encapsulation and tablet compression. American Pharmaceutical Review (Vol. 2, pp. 1-5). Retrieved on July 6, 2003 from: [http://www.americanpharmaceuticalreview.com.currentissue/2 APR S.../McCarty\\_article.ht](http://www.americanpharmaceuticalreview.com.currentissue/2%20APR%20S.../McCarty_article.ht).
- [70] Marshall K. (1986). Compression and consolidation of powdered solids. In: Lachman L., Lieberman H.A., and Kanig J.L., editors. The Theory and Practice of Industrial Pharmacy (3<sup>rd</sup> ed.). Philadelphia: Lea & Febiger.
- [71] Lantz R.J. (1990). Size reduction. In: Lieberman H.A., Lachman L., and Schwartz J.B., editors. Pharmaceutical Dosage Forms: Tablets. (2<sup>nd</sup> ed.). New York: Marcel Dekker.
- [72] Aulton M.E. (1990). Pharmaceutics: The Science of Dosage Form Design. Hong Kong: ELBS imprint.
- [73] Amodon G.E. (1995). Physical and Mechanical Property Characterization of Powders. In: Brittain H.G, editor. Physical Characterization of Pharmaceutical Solids. New York: Marcel Dekker.



- [74] Rudnic E.M., & Kottke M.K. (1996). Tablet dosage forms. In: Banker G.S., and Rhodes C.T., editors. Modern Pharmaceutics. (3<sup>rd</sup> ed.). New York: Marcel Dekker.
- [75] Gordon R.E. (1990). Rosanske T.W., Fonner D.E., Anderson N.R., and Banker G.S., Granulation technology and tablet characterization. In: Lieberman H.A., Lachman L., and Schwartz J.B., editors. Pharmaceutical Dosage Forms: Tablets. (2<sup>nd</sup> ed.). New York: Marcel Dekker.
- [76] Wadke D.A., Serajuddin A.T.M., & Jacobson H. (1990). Preformulation testing. In: Lieberman H.A., Lachman L., and Schwartz J.B., editors. Pharmaceutical Dosage Forms: Tablets. (2<sup>nd</sup> ed.). New York: Marcel Dekker.
- [77] Te Wierik G.H.P., Eissens A.C., & Lerk C.F. (1993). Preparation, characterization and pharmaceutical application of linear dextrans: IV. Drug release from capsules and tablets containing amyloextrin. International Journal of Pharmaceutics, (98), 219-224.
- [78] Simonelli A.P., Mehta S.C., & Higushi W.I. (1969). Dissolution rate of high energy polyvinylpyrrolidone(PVP)-sulfathiazole coprecipitates. Journal of Pharmaceutical Sciences, 58(5), 538-548.
- [79] Badawy S.I.F., Ghorab M.M., & Adeyeye C.M. (1996). Characterization and bioavailability of danazol-hydroxypropyl –cyclodextrin coprecipitates. International Journal of Pharmaceutics, (128), 45-54.
- [80] Abdul-Fattah A.M., & Bhargava H.N. (2002). Preparation and in vitro evaluation of solid dispersions of halofantrine. International Journal of Pharmaceutics, (235), 17-33.
- [81] Jinda K.C. et al. (1995). Effect of particle size on the bioavailability and dissolution rate of rifampicin. Indian Drug, 32(3), 100-107.
- [82] Warwick B. et al. (2002). Micronization of copper indomethacin using gas antisolvent processes. Industrial and Engineering Chemistry Research, (41), 1993-2004.

- [83] Hintz R.J. & Johnson K.C. (1989). The effect of particle size distribution on dissolution rate and oral absorption. International Journal of Pharmaceutics, (51), 9-17.
- [84] York P. (1980). Studies of the effect of powder moisture content on drug release from hard gelatin capsules. Drug Development and Industrial Pharmacy, 6(6), 605-627.
- [85] Fell J.T., Calvert R.T., & Riley-Bentham P. (1978). Bioavailability of griseofulvin from a novel capsule formulation. Journal of Pharmaceutical Pharmacology, (30), 479-482.
- [86] Ridgway K. (1987). Hard capsules development and technology. London: Pharmaceutical Press.
- [87] York P. (1983). Solid-state properties of powders in the formulation and processing of solid dosage forms. International Journal of Pharmaceutics, (14), 1-28.
- [88] Bolhuis G.K., Zuurman K., & Te wierik. (1997). Improvement of dissolution of poorly soluble drugs by solid deposition on a super disintegrant. II. The choice of super disintegrants and effect of granulation. European Journal of Pharmaceutical Sciences, (5), 63-69.
- [89] Gao J.Z.H. et al. (2002). Fluid bed granulation of a poorly water soluble, low density, micronized drug: comparison with high shear granulation. International Journal of Pharmaceutics, (237), 1-14.
- [90] Ministry of Health. No. 455. Ministerial request to Phnom Penh municipality on implementing of closing of illegal drugstores in Phnom Penh city. June 27, 2000.